cro.directory
← Compare landing

IQVIA vs ICON

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/iqvia/kcrcro

CategoryIQVIAICON
Listed sitecrocro
SummaryIQVIA is a global life sciences and healthcare company providing data, expertise, AI, analytics, and technology solutions to support clinical development and improve patient outcomes.ICON is a CRO with 8,000 biotech-dedicated professionals offering end-to-end clinical development, consulting, and therapeutic expertise across all development phases.
Services
  • Data Management & eClinical
  • Biostatistics & Statistical Programming
  • Medical Writing
  • Regulatory Affairs
  • Pharmacovigilance & Drug Safety
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • Central Laboratory Services
  • China NMPA Regulatory Strategy
  • Biomarker Assays
  • Bioanalysis
  • Clinical Imaging Core Lab
  • Translational Research
  • Immunogenicity Assays (ADA / NAb)
  • Bioinformatics & Data Science
  • Cardiovascular & Metabolic Specialty Services
  • CNS Specialty Services
  • Oncology Specialty Services
  • Immunology & Inflammation Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • Clinical Imaging Core Lab
  • Central Laboratory Services
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Regulatory Affairs
  • Medical Writing
  • Cardiovascular & Metabolic Specialty Services
  • CNS Specialty Services
  • Oncology Specialty Services
  • Immunology & Inflammation Services
  • Virology Services
  • Biostatistics & Statistical Programming
  • Data Management & eClinical
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
Modalities
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
Indications
  • Cardiovascular
  • Neurology
  • Dermatology
  • Ophthalmology
  • Gastroenterology
  • Nephrology
  • Respiratory
  • Infectious Disease
  • Oncology
  • Rare Disease
  • Immunology
  • Metabolic
  • Psychiatry
  • Women's Health
  • Oncology
  • Neurology
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Women's Health
Locations
  • Global presence, Multiple
  • Global presence, Multiple regions
  • Argentina, Buenos Aires, Buenos Aires, Argentina
Data not yet provided.
CertificationsData not yet provided.Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.